What's new in transplantation

Journal of the American College of Surgeons

Volumn 194, Issue 5, 2002, Pages 636-641

  Emond, Jean C ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

CELL TRANSPLANTATION; ETHICS; HEALTH CARE POLICY; HEART TRANSPLANTATION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE TRANSPLANTATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PUBLIC OPINION; REVIEW; TRANSPLANTATION;

EID: 0036256177     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1072-7515(02)01161-4     Document Type: Article

References (44)

1. Inequities in liver transplant allocation
2. MELD and PELD: Application of survival models to liver allocation
3. The donor's right to take a risk
4. Transplantation of liver grafts from living donors into adults - Too much, too soon
5. Life or death. The issue of payment in cadaveric organ donation
6. Financial compensation for cadaver organ donation: An ethical reappraisal
7. Expanding the organ donor pool: The Spanish Model
8. Blocking costimulatory signals to induce transplantation tolerance and prevent autoimmune disease
9. CTLA4-Ig: A novel immunosuppressire agent
10. Induction of cytotoxic T lymphocyte antigen 4 (CTLA-4) restricts clonal expansion of helper T cells
11. Monoclonal antibodies and other biologic therapies
12. The mystique of hepatic tolerogenicity
13. Preimplantation-stage stem cells induce long-term allogeneic graft acceptance without supplementary host conditioning
14. Sirolimus: A comprehensive review
15. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: One-year angiographic and intravascular ultrasound follow-up
16. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis
17. Rapamycin's resurrection: A new way to target the cancer cell cycle
18. Current and novel immunosuppressive therapy for autoimmune hepatitis
19. Steroid side effects and their impact on transplantation outcome
20. Adult liver transplantation and steroid-azathioprine withdrawal in cyclosporine. (Sandimmun)-based immunosuppression-5 year results of a prospective study
21. Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil
22. Diabetes. Islet cell transplantation
23. Islet cell transplantation for the treatment of diabetes mellitus
24. Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation
25. A bioartificial liver - State of the art
26. The Registry of the International Society for Heart and Lung Transplantation: Eighteenth Official Report-2001
27. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group long-term mechanical left ventricular assistance for end-stage heart failure
28. Chimerism of the transplanted heart
29. Assessment of survival benefit after lung transplantation by patient diagnosis
30. Active "donor management" strategies may increase organ availability in lung transplantation
31. Risk factors for bronchiolitis obliterans: A systematic review of recent publications
32. Living donor lung transplantation
33. Preliminary results of a liver allocation plan using a continuous medical severity score that de-emphasizes waiting time
34. Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virus-reinfected liver
35. Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: A pragmatic study
36. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C
37. Small bowel transplantation: Selection criteria, operative techniques, advances in specific immunosuppression, prognosis
38. Late graft loss and long-term outcome after isolated intestinal transplantation in children
39. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus
40. Intestinal transplantation before and after the introduction of sirolimus
41. Expanded criteria donors/high risk recipients is not always cheaper than hemodialysis
42. Laparoscopic live donor nephrectomy. A review of the first 5 years
43. Randomized controlled trial of hand-assisted laparoscopic versus open surgical live donor nephrectomy